Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics
Ulldemolins, Anna (Vall d'Hebron Institut de Recerca (VHIR))
Seras-Franzoso, Joaquin (Vall d'Hebron Institut de Recerca (VHIR))
Andrade, Fernanda (Instituto de Salud Carlos III)
Rafael, Diana (Instituto de Salud Carlos III)
Abasolo, Ibane (Instituto de Salud Carlos III)
Gener, Petra (Instituto de Salud Carlos III)
Schwartz, Simon (Instituto de Salud Carlos III)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well.
Ajuts:	Instituto de Salud Carlos III PI17/02242 Instituto de Salud Carlos III PI20/01474 European Commission 800983
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Drug delivery systems ; Resistance ; Nanomedicine ; Cancer treatment
Publicat a:	Cancer Drug Resistance, Vol. 4 (march 2021) , p. 44-68, ISSN 2578-532X

DOI: 10.20517/cdr.2020.59
PMID: 35582007

25 p, 6.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats